Abstract:OBJECTIVE To evaluate the effect of thymosin alpha 1 on the prognosis of patients with coronavirus disease 2019 (COVID-19). METHODS A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19. They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission. The 28-day mortality (primary outcome), and 28-ventilator-free-day, lymphocyte count (LYM) level, C-reactive protein (CRP) level (secondary outcomes) were compared between two groups. Survival analysis was performed using the Kaplan-Meier curve. The effect of thymosin alpha 1 on 28-day survival was evaluated with Cox regression model. RESULTS Among the 95 patients, there were 31 cases in thymosin group and 64 cases in non-thymosin group; 29 patients died 28 days after admission, including 11 cases (35.5%) in thymosin group and 18 cases (28.1%) in non-thymosin group. Kaplan-Meier survival curve showed that thymosin alpha 1 could improve the 28-day survival of patients with COVID-19, but the univariate Cox model analysis showed that the difference was not statistically significant [hazard ratio (HR) = 0.48, 95% confidence interval (95%CI) was 0.20-1.14, P = 0.098]; multivariate Cox model analysis showed that thymosin alpha 1 was the factor to improve the 28-day mortality (HR = 0.15, 95%CI was 0.04-0.55, P = 0.004), old age (HR = 1.10, 95%CI was 1.05-1.15, P < 0.001), accompanied by chronic renal dysfunction (HR = 42.35, 95%CI was 2.77-648.64, P = 0.007), decrease of LYM at admission (HR = 0.15, 95%CI was 0.04-0.60, P = 0.007) and the use of methylprednisolone (HR = 4.59, 95%CI was 1.26-16.67, P = 0.021) were also risk factors for the increase of 28-day mortality. The use of immunoglobulin and antiviral drugs abidol and ganciclovir did not affect the 28-day mortality. After adjustment for age, gender, LYM and other factors, weighted multivariate Cox analysis model showed thymosin alpha 1 could significantly improve the 28-day survival of COVID-19 patients (HR = 0.45, 95%CI was 0.25-0.84, P = 0.012). In terms of secondary outcomes, no statistical difference (all P > 0.05) was found between two groups in days without ventilator at 28 days after admission (days: 17.97±13.56 vs. 20.09±12.67) and the increase of LYM at 7 days after admission [×109/L: -0.07 (-0.23, 0.43) vs. 0.12 (-0.54, 0.41)]. But the decrease of CRP at 7 days after admission in thymosin alpha group was significantly greater than that in non-thymosin group [mg/L: 39.99 (8.44, 82.22) vs. 0.53 (-7.78, 22.93), P < 0.05]. CONCLUSION Thymosin alpha 1 may improve 28-day mortality and inflammation state in COVID-19 patients.

Efficacy of Thymalfasin New Adjuvant Therapy in Treating Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Influence on Cellular Immune Function

Effects of combination treatment with theophylline sustained release tablets and thymalfasin on pulmonary function, immunity, and inflammation in elderly patients with chronic obstructive pulmonary disease and respiratory failure

Clinical Effects of Thymosin α_1 in the Adjuvant Treatment of Elderly Patients with AECOPD

Effect of Thymosin A1 on Complications after Laparoscopic Pancreaticoduodenectomy in Elderly Patients

Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Effect of Thymosin Alpha 1 on Cellular Immune Function in Elderly Patients with Malignant Tumor

Cellular immune function changes and effect of thymosin alpha-1 on the changes in elderly patients with severe pneumonia

Clinical Study of Thymosin α1 Combined with Pemetrexed in the Treatment of Elderly Patients with Advanced Lung Adenocarcinoma

Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms

The effect of adjuvant therapy with ambroxol hydrochloride in elderly chronic obstructive pulmonary disease patients

Efficacy of Thymosin α1 on Cell Immunity of Elderly Patients with Severe Ventilator-associated pneumonia

Changes of Metailoproteinase-9, Tissue Inhibitor of Metalloproteinase-1 and Interleukin-8 in Elderly Patients with Chronic Obstructive Pulmonary Disease and the Effects of Different Drugs

Clinical Efficacy of Inhaled Glucocorticoids Combined with Streptococcus Pneumoniae Vaccines for Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Elderly Patients

Effectiveness of Thymosin Alpha-1 on Patients with Severe Community-Acquired Pneumonia

Immunological Functions of T-lymphocyte in the Elderly with Chronic Obstructive Pulmonary Disease During Acute Exacerbations and Medication Intervention

Evaluation of fiber bronchoscope in treating elderly patients with acute severelung infection and pulmonary atelectasis

Effect of Mannatide Capsules in Treating Stable Stage of Chronic Obstructive Pulmonary Disease

Research on the Significance of Thymosin Α1 for Infection Risk and Prognosis in Elderly Lung Cancer Patients Received Chemotherapy

Clinical Efficacy Observation of Acetylcysteine Combined with Tiotropium Bromide Inhalation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

[Thymosin Alpha 1 for the Adjuvant Treatment of Coronavirus Disease 2019: a Retrospective Cohort Study].

Application of fiberoptic bronchoscopy in elderly patients with acute exacerbation of chronic obstructive pulmonary disease